The Case of Dr. Andrew Hill: Was there Unethical Activity Associated with his Ivermectin Meta-Analysis or Just Another Drug Dev Day?

By late last year with mounting numbers of ivermectin clinical trials, mostly from low-and middle-income countries (LMICs), the potential for ivermectin as a treatment for COVID-19 gained significant movement. Key studies from McMaster’s TOGETHER study to a meta-analysis authored by Dr. Andrew Hill, affiliated with the University of Liverpool, and Unitaid—affiliated organization of the World Health Organization (WHO)—were to pave the way for use of the low cost, repurposed drug. But due to a purported under-dosing in the TOGETHER study and some questionable last-minute changes in the Unitaid-sponsored Hill meta-analysis, the pro-ivermectin consensus went south. With pharmaceutical companies developing vaccines in support of a universal vaccination program, any low-cost alternatives for early care weren’t well supported by any influencers in the medical establishments of North America and Europe. Additional companies such as Gilead, Merck, AstraZeneca, Regeneron, and Pfizer were busy securing in the aggregate billions of taxpayer dollars to develop antivirals and monoclonal antibodies. The market for early-stage antiviral care for mild-to-moderate COVID-19 involves ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee